Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose

Jennifer Hislop; Graham Mowatt; Pawana Sharma; Cynthia Fraser; Andrew Elders; David Jenkinson; Luke Vale; Russell Petty

doi:10.1007/s12029-011-9325-6

Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose

Jennifer Hislop
, Graham Mowatt
, Pawana Sharma
, Cynthia Fraser
, Andrew Elders
, David Jenkinson
, Luke Vale
, Russell Petty

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

11 Downloads (Pure)

Original language	English
Pages (from-to)	168-176
Number of pages	9
Journal	Journal of Gastrointestinal Cancer
Volume	43
Issue number	2
Early online date	6 Oct 2011
DOIs	https://doi.org/10.1007/s12029-011-9325-6
Publication status	Published - Jun 2012

Bibliographical note

PMID: 21971958 [PubMed - indexed for MEDLINE] PMCID: PMC3348468 Free PMC Article

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

GIST
gastrointestinal stromal tumours
unresectable
metastatic
cancer
imatinib
sunitinib
antineoplastic agents
benzamides
clinical trials as topic
disease progression
dose-response relationship
gastrointestinal stromal tumors
humans
indoles
piperazines
pyrimidines
pyrroles
treatmemnt outcome

Access to Document

10.1007/s12029-011-9325-6

Hislop 2012
The original publication is available at www.springerlink.com. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
Final published version, 213 KB

Cite this

Hislop, J., Mowatt, G., Sharma, P., Fraser, C., Elders, A., Jenkinson, D., Vale, L., & Petty, R. (2012). Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose. Journal of Gastrointestinal Cancer, 43(2), 168-176. https://doi.org/10.1007/s12029-011-9325-6

Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose. / Hislop, Jennifer; Mowatt, Graham; Sharma, Pawana et al.
In: Journal of Gastrointestinal Cancer, Vol. 43, No. 2, 06.2012, p. 168-176.

Research output: Contribution to journal › Article › peer-review

Hislop, J, Mowatt, G, Sharma, P, Fraser, C, Elders, A, Jenkinson, D, Vale, L & Petty, R 2012, 'Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose', Journal of Gastrointestinal Cancer, vol. 43, no. 2, pp. 168-176. https://doi.org/10.1007/s12029-011-9325-6

Hislop J, Mowatt G, Sharma P, Fraser C, Elders A, Jenkinson D et al. Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose. Journal of Gastrointestinal Cancer. 2012 Jun;43(2):168-176. Epub 2011 Oct 6. doi: 10.1007/s12029-011-9325-6

Hislop, Jennifer ; Mowatt, Graham ; Sharma, Pawana et al. / Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose. In: Journal of Gastrointestinal Cancer. 2012 ; Vol. 43, No. 2. pp. 168-176.

@article{220ee7d835d94225b8f31ba7e6dbe804,

title = "Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose",

keywords = "GIST, gastrointestinal stromal tumours, unresectable, metastatic, cancer, imatinib, sunitinib, antineoplastic agents, benzamides, clinical trials as topic, disease progression, dose-response relationship, gastrointestinal stromal tumors, humans, indoles, piperazines, pyrimidines, pyrroles, treatmemnt outcome",

author = "Jennifer Hislop and Graham Mowatt and Pawana Sharma and Cynthia Fraser and Andrew Elders and David Jenkinson and Luke Vale and Russell Petty",

note = "PMID: 21971958 [PubMed - indexed for MEDLINE] PMCID: PMC3348468 Free PMC Article This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited",

year = "2012",

month = jun,

doi = "10.1007/s12029-011-9325-6",

language = "English",

volume = "43",

pages = "168--176",

journal = "Journal of Gastrointestinal Cancer",

issn = "1941-6628",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose

AU - Hislop, Jennifer

AU - Mowatt, Graham

AU - Sharma, Pawana

AU - Fraser, Cynthia

AU - Elders, Andrew

AU - Jenkinson, David

AU - Vale, Luke

AU - Petty, Russell

N1 - PMID: 21971958 [PubMed - indexed for MEDLINE] PMCID: PMC3348468 Free PMC Article This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited

PY - 2012/6

Y1 - 2012/6

KW - GIST

KW - gastrointestinal stromal tumours

KW - unresectable

KW - metastatic

KW - cancer

KW - imatinib

KW - sunitinib

KW - antineoplastic agents

KW - benzamides

KW - clinical trials as topic

KW - disease progression

KW - dose-response relationship

KW - gastrointestinal stromal tumors

KW - humans

KW - indoles

KW - piperazines

KW - pyrimidines

KW - pyrroles

KW - treatmemnt outcome

U2 - 10.1007/s12029-011-9325-6

DO - 10.1007/s12029-011-9325-6

M3 - Article

SN - 1941-6628

VL - 43

SP - 168

EP - 176

JO - Journal of Gastrointestinal Cancer

JF - Journal of Gastrointestinal Cancer

IS - 2

ER -